TY  - JOUR
AU  - Abid, Leila
AU  - Kammoun, Ikram
AU  - Ben Halima, Manel
AU  - Charfeddine, Salma
AU  - Ben Slima, Hedi
AU  - Drissa, Meriem
AU  - Mzoughi, Khadija
AU  - Mbarek, Dorra
AU  - Riahi, Leila
AU  - Antit, Saoussen
AU  - Ben Halima, Afef
AU  - Ouechtati, Wejdene
AU  - Allouche, Emna
AU  - Mechri, Mehdi
AU  - Yousfi, Chedi
AU  - Khorchani, Ali
AU  - Abid, Omar
AU  - Sammoud, Kais
AU  - Ezzaouia, Khaled
AU  - Gtif, Imen
AU  - Ouali, Sana
AU  - Triki, Feten
AU  - Hamdi, Sonia
AU  - Boudiche, Selim
AU  - Chebbi, Marwa
AU  - Hentati, Mouna
AU  - Farah, Amani
AU  - Triki, Habib
AU  - Ghardallou, Houda
AU  - Raddaoui, Haythem
AU  - Zayed, Sofien
AU  - Azaiez, Fares
AU  - Omri, Fadwa
AU  - Zouari, Akram
AU  - Ben Ali, Zine
AU  - Najjar, Aymen
AU  - Thabet, Houssem
AU  - Chaker, Mouna
AU  - Mohamed, Samar
AU  - Chouaieb, Marwa
AU  - Ben Jemaa, Abdelhamid
AU  - Tangour, Haythem
AU  - Kammoun, Yassmine
AU  - Bouhlel, Mahmoud
AU  - Azaiez, Seifeddine
AU  - Letaief, Rim
AU  - Maskhi, Salah
AU  - Amri, Aymen
AU  - Naanaa, Hela
AU  - Othmani, Raoudha
AU  - Chahbani, Iheb
AU  - Zargouni, Houcine
AU  - Abid, Syrine
AU  - Ayari, Mokdad
AU  - ben Ameur, Ines
AU  - Gasmi, Ali
AU  - ben Halima, Nejeh
AU  - Haouala, Habib
AU  - Boughzela, Essia
AU  - Zakhama, Lilia
AU  - ben Youssef, Soraya
AU  - Nasraoui, Wided
AU  - Boujnah, Mohamed Rachid
AU  - Barakett, Nadia
AU  - Kraiem, Sondes
AU  - Drissa, Habiba
AU  - Ben Khalfallah, Ali
AU  - Gamra, Habib
AU  - Kachboura, Salem
AU  - Bezdah, Leila
AU  - Baccar, Hedi
AU  - Milouchi, Sami
AU  - Sdiri, Wissem
AU  - Ben Omrane, Skander
AU  - Abdesselem, Salem
AU  - Kanoun, Alifa
AU  - Hezbri, Karima
AU  - Zannad, Faiez
AU  - Mebazaa, Alexandre
AU  - Kammoun, Samir
AU  - Mourali, Mohamed Sami
AU  - Addad, Faouzi
PY  - 2021
DA  - 2021/10/27
TI  - Design and Rationale of the National Tunisian Registry of Heart Failure (NATURE-HF): Protocol for a Multicenter Registry Study
JO  - JMIR Res Protoc
SP  - e12262
VL  - 10
IS  - 10
KW  - heart failure
KW  - acute heart failure
KW  - chronic heart failure
KW  - diagnosis
KW  - prognosis
KW  - treatment
AB  - Background: The frequency of heart failure (HF) in Tunisia is on the rise and has now become a public health concern. This is mainly due to an aging Tunisian population (Tunisia has one of the oldest populations in Africa as well as the highest life expectancy in the continent) and an increase in coronary artery disease and hypertension. However, no extensive data are available on demographic characteristics, prognosis, and quality of care of patients with HF in Tunisia (nor in North Africa). Objective: The aim of this study was to analyze, follow, and evaluate patients with HF in a large nation-wide multicenter trial. Methods: A total of 1700 patients with HF diagnosed by the investigator will be included in the National Tunisian Registry of Heart Failure study (NATURE-HF). Patients must visit the cardiology clinic 1, 3, and 12 months after study inclusion. This follow-up is provided by the investigator. All data are collected via the DACIMA Clinical Suite web interface. Results: At the end of the study, we will note the occurrence of cardiovascular death (sudden death, coronary artery disease, refractory HF, stroke), death from any cause (cardiovascular and noncardiovascular), and the occurrence of a rehospitalization episode for an HF relapse during the follow-up period. Based on these data, we will evaluate the demographic characteristics of the study patients, the characteristics of pathological antecedents, and symptomatic and clinical features of HF. In addition, we will report the paraclinical examination findings such as the laboratory standard parameters and brain natriuretic peptides, electrocardiogram or 24-hour Holter monitoring, echocardiography, and coronarography. We will also provide a description of the therapeutic environment and therapeutic changes that occur during the 1-year follow-up of patients, adverse events following medical treatment and intervention during the 3- and 12-month follow-up, the evaluation of left ventricular ejection fraction during the 3- and 12-month follow-up, the overall rate of rehospitalization over the 1-year follow-up for an HF relapse, and the rate of rehospitalization during the first 3 months after inclusion into the study. Conclusions: The NATURE-HF study will fill a significant gap in the dynamic landscape of HF care and research. It will provide unique and necessary data on the management and outcomes of patients with HF. This study will yield the largest contemporary longitudinal cohort of patients with HF in Tunisia. Trial Registration: ClinicalTrials.gov NCT03262675; https://clinicaltrials.gov/ct2/show/NCT03262675 International Registered Report Identifier (IRRID): DERR1-10.2196/12262 
SN  - 1929-0748
UR  - https://www.researchprotocols.org/2021/10/e12262
UR  - https://doi.org/10.2196/12262
UR  - http://www.ncbi.nlm.nih.gov/pubmed/34704958
DO  - 10.2196/12262
ID  - info:doi/10.2196/12262
ER  -